Please Wait
Applying Filters...
menu
    • menu
    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    Vamsi labs Salmeterol Xinafoate

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Salmeterol Xinafoate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 39,700Xls

    Filters

    clear-filterReset all filters
    2D Structure
    Also known as: 94749-08-3, Salmetedur, Arial, Gr 33343x xinafoate, Salmeterol 1-hydroxy-2-naphthoate, Salmeterolo
    Molecular Formula
    C36H45NO7
    Molecular Weight
    603.7  g/mol
    InChI Key
    XTZNCVSCVHTPAI-UHFFFAOYSA-N
    FDA UNII
    6EW8Q962A5
    A selective ADRENERGIC BETA-2 RECEPTOR agonist that functions as a BRONCHODILATOR when administered by inhalation. It is used to manage the symptoms of ASTHMA and CHRONIC OBSTRUCTIVE PULMONARY DISEASE.
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    2-(hydroxymethyl)-4-[1-hydroxy-2-[6-(4-phenylbutoxy)hexylamino]ethyl]phenol;1-hydroxynaphthalene-2-carboxylic acid
    2.1.2 InChI
    InChI=1S/C25H37NO4.C11H8O3/c27-20-23-18-22(13-14-24(23)28)25(29)19-26-15-7-1-2-8-16-30-17-9-6-12-21-10-4-3-5-11-21;12-10-8-4-2-1-3-7(8)5-6-9(10)11(13)14/h3-5,10-11,13-14,18,25-29H,1-2,6-9,12,15-17,19-20H2;1-6,12H,(H,13,14)
    2.1.3 InChI Key
    XTZNCVSCVHTPAI-UHFFFAOYSA-N
    2.1.4 Canonical SMILES
    C1=CC=C(C=C1)CCCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O.C1=CC=C2C(=C1)C=CC(=C2O)C(=O)O
    2.2 Other Identifiers
    2.2.1 UNII
    6EW8Q962A5
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. Salmeterol

    2. Serevent

    3. Xinafoate, Salmeterol

    2.3.2 Depositor-Supplied Synonyms

    1. 94749-08-3

    2. Salmetedur

    3. Arial

    4. Gr 33343x Xinafoate

    5. Salmeterol 1-hydroxy-2-naphthoate

    6. Salmeterolo

    7. Salmeterol (xinafoate)

    8. 4-(1-hydroxy-2-((6-(4-phenylbutoxy)hexyl)amino)ethyl)-2-(hydroxymethyl)phenol 1-hydroxy-2-naphthoate

    9. Gr 33343 G

    10. 2-(hydroxymethyl)-4-[1-hydroxy-2-[6-(4-phenylbutoxy)hexylamino]ethyl]phenol;1-hydroxynaphthalene-2-carboxylic Acid

    11. Serevent Diskus

    12. 6ew8q962a5

    13. Gr-33343x

    14. Gr-33343 G

    15. Ncgc00094372-03

    16. Asmerole

    17. Betamican

    18. Dilamax

    19. Inaspir

    20. Ultrabeta

    21. Beglan

    22. Dsstox_cid_25798

    23. Dsstox_rid_81137

    24. Dsstox_gsid_45798

    25. Serevent Inhaler And Disks

    26. Salmeterol Xinafoate [usan]

    27. Smr000875207

    28. Cas-94749-08-3

    29. Unii-6ew8q962a5

    30. Salmeterol Xinafoate [usan:usp]

    31. Serevent (tn)

    32. 4-[1-hydroxy-2-[[6-(4-phenylbutoxy)hexyl]amino]ethyl]-2-(hydroxymethyl)phenol 1-hydroxy-2-naphthoate

    33. Salmeterol, 1-hydroxy-2-naphthoate

    34. Mfcd00897708

    35. Schembl18070

    36. (+-)-4-hydroxy-alpha(sup 1)-(((6-(4-phenylbutoxy)hexyl)amino)methyl)-m-xylene-alpha,alpha'-diol 1-hydroxy-2-naphthoate (salt)

    37. Mls001332577

    38. Mls001332578

    39. Chebi:9012

    40. Lipo-202

    41. Chembl1082607

    42. Dtxsid1045798

    43. Salmeterol Xinafoate (jan/usp)

    44. Hms2232i16

    45. Hms3263k22

    46. Hms3676p13

    47. Hms3749i03

    48. Hms3885j19

    49. Salmeterol Xinafoate [jan]

    50. Amy23373

    51. Bcp04778

    52. Salmeterol Xinafoate [vandf]

    53. Tox21_111270

    54. Tox21_501100

    55. S4296

    56. Salmeterol Xinafoate [mart.]

    57. Salmeterol Xinafoate [usp-rs]

    58. Salmeterol Xinafoate [who-dd]

    59. Akos016004957

    60. Tox21_111270_1

    61. Ccg-270203

    62. Cs-1527

    63. Ks-1140

    64. Lp01100

    65. Ncgc00015938-05

    66. Ncgc00094372-01

    67. Ncgc00094372-02

    68. Ncgc00094372-04

    69. Ncgc00261785-01

    70. 1,3-benzenedimethanol, 4-hydroxy-alpha(sup 1)-(((6-(4-phenylbutoxy)hexyl)amino)methyl)-, (+-)-, 1-hydroxy-2-naphthalenecarboxylate (salt)

    71. Hy-17453

    72. Salmeterol Xinafoate [ep Impurity]

    73. Salmeterol Xinafoate [orange Book]

    74. Bcp0726000003

    75. Salmeterol Xinafoate [ep Monograph]

    76. Advair Component Salmeterol Xinafoate

    77. Db-057527

    78. Salmeterol Xinafoate [usp Monograph]

    79. Eu-0101100

    80. Ft-0642283

    81. Salmeterol Xinafoate, >=98% (hplc), Solid

    82. D00687

    83. Lipo-102 Component Salmeterol Xinafoate

    84. R10007

    85. Salmeterol 1-hydroxy-2-naphthoate [mi]

    86. Salmeterol Xinafoate Component Of Advair

    87. Advair Hfa Component Salmeterol Xinafoate

    88. A916443

    89. Sr-01000597359

    90. Q-201697

    91. Salmeterol Xinafoate Component Of Advair Hfa

    92. Sr-01000597359-1

    93. Airduo Respiclick Component Salmeterol Xinafoate

    94. Q27264747

    95. Salmeterol Xinafoate Component Of Airduo Respiclick

    96. Salmeterol Xinafoate, European Pharmacopoeia (ep) Reference Standard

    97. Salmeterol Xinafoate, United States Pharmacopeia (usp) Reference Standard

    98. Salmeterol Xinafoate For System Suitability, European Pharmacopoeia (ep) Reference Standard

    99. Salmeterol Xinafoate, Pharmaceutical Secondary Standards; Certified Reference Material

    100. (+/-)-4-hydroxy-.alpha.(sup 1)-(((6-(4-phenylbutoxy)hexyl)amino)methyl)-m-xylene-.alpha.,.alpha.'-diol 1-hydroxy-2-naphthoate

    101. 1,3-benzenedimethanol, 4-hydroxy-.alpha.(sup 1)-(((6-(4-phenylbutoxy)hexyl)amino)methyl)-, (+/-)-, 1-hydroxy-2-naphthalenecarboxylate

    102. 4-(1-hydroxy-2-(6-(4-phenylbutoxy)hexylamino)ethyl)-2-(hydroxymethyl)phenol 1-hydroxy-2-naphthoate

    103. 4-hydroxy-?1-[[[6-(4-phenylbutoxy)hexyl]amino]methyl]-1,3-benzenedimethanol 1-hydroxy-2-naphthalenecarboxylic Acid Salt

    2.4 Create Date
    2005-06-24
    3 Chemical and Physical Properties
    Molecular Weight 603.7 g/mol
    Molecular Formula C36H45NO7
    Hydrogen Bond Donor Count6
    Hydrogen Bond Acceptor Count8
    Rotatable Bond Count17
    Exact Mass603.31960277 g/mol
    Monoisotopic Mass603.31960277 g/mol
    Topological Polar Surface Area140 Ų
    Heavy Atom Count44
    Formal Charge0
    Complexity629
    Isotope Atom Count0
    Defined Atom Stereocenter Count0
    Undefined Atom Stereocenter Count1
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count2
    4 Pharmacology and Biochemistry
    4.1 MeSH Pharmacological Classification

    Bronchodilator Agents

    Agents that cause an increase in the expansion of a bronchus or bronchial tubes. (See all compounds classified as Bronchodilator Agents.)

    Adrenergic beta-2 Receptor Agonists

    Compounds bind to and activate ADRENERGIC BETA-2 RECEPTORS. (See all compounds classified as Adrenergic beta-2 Receptor Agonists.)

    4.2 FDA Pharmacological Classification
    4.2.1 Pharmacological Classes
    beta2-Adrenergic Agonist [EPC]; Adrenergic beta2-Agonists [MoA]